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Here we show that human papillomavirus (HPV) E6 and E7 oncoproteins induce hWAPL expression. In addition, small interfering
RNA (siRNA) of hWAPL suppressed the growth of tumours derived from SiHa cells in nude mice. Thus, hWAPL may be one of the
effective targets of uterine cervical cancer therapy.
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Cervical cancer is unique due to its association with high-
risk human papilloma virus (HPV) infection with strains such
as HPV-16 and HPV-18 (zur Hausen, 1996). The high-risk-
HPV oncoproteins, E6 and E7, are necessary for immortalisation
and transformation of cervical keratinocytes (Munger et al, 1989).
E6 binds to the wild-type p53 protein and promotes its ubiqui-
tin-dependent degradation (Scheffner et al, 1990, 1993), and E7
binds to the retinoblastoma protein Rb and disrupts the complex
between Rb and the E2F transcription factor family, which
controls the expression of genes involved in cell-cycle progression
(Dyson et al, 1992). Therefore, the development of anticancer
therapies that target HPV E6 and E7 and/or downstream targets
of HPV E6 and E7 might be a specific and effective treat-
ment for cervical cancer. In fact, RNA interference (RNAi) of
E6 and/or E7 inhibits growth of HPV-positive cancer cells
(Jiang and Milner, 2002; Butz et al, 2003; Yoshinouchi et al,
2003).
Our previous study demonstrated that the novel human gene
hWAPL showed the unscheduled high-level expression in cervical
dysplasia and carcinoma (Oikawa et al, 2004). In addition, NIH3T3
cells overexpressing hWAPL developed into tumours upon
injection into nude mice, suggesting that hWAPL plays a
significant role in cervical carcinogenesis and tumour progression
as an oncogene (Oikawa et al, 2004). Furthermore, siRNA of
hWAPL inhibited cell growth in cervical cancer-derived cultured
cells (Oikawa et al, 2004).
In this report, we reveal that HPV E6 and E7 oncoproteins affect
hWAPL expression. We also show that hWAPL exhibited great
potential as a novel therapeutic target molecule in the treatment of
cervical cancer.
MATERIALS AND METHODS
Cell culture, retroviral vector construction and retroviral
infection
SiHa, CaSki and C33A cells were grown in DMEM (Sigma Chemical
Co. , St Louis, MO, USA) containing 10% fetal bovine serum (FBS)
at 371C in a 5% CO2 environment. Normal human epidermal
keratinocytes from adult skin (HDK1) were grown in keratinocyte
serum-free medium (K-SFM; Invitrogen, Carlsbad, CA, USA).
The HPV16-E6, E7, and E6E7 genes were amplified by
polymerase chain reaction (PCR) using the following primers: 50-
AAAAAGCAGGCTCCACCATGTTTCAGGACCCACAGGAGCGACC
C-30 and 50-AGAAAGCTGGGTTACAGCTGGGTTTCTCTACGTG-30
for E6, and 50-AAAAAGCAGGCTCCACCATGCATGGAGATACA
CCTACAT-30 and 50-AGAAAGCTGGGTTATGGTTTCTGAGAACA
GATGGGG-30 for E7. The amplified DNA fragments were cloned
into the retroviral vector, pCLXSN.
The bovine papillomavirus type 1 (BPV1) E2 segment was
obtained by nested PCR from a pBPV-MII template using 50-
GGGGACAAGTTTGTACAAAAAAGCAGGCT-30 and 50-GGGGAC
CACTTTGTACAAGAAAGCTGGGT-30 as outer primers, and 50-
AAAAAGCAGGCTCCACCATGGAGACAGCATGCGAAC-30 and 50-
AGAAAGCTGGGTCAGAAGTCCAAGCTGGCTGTAAAG-30 as in-
ner primers. The BPV1 E2 segment was then cloned into a
pCMSCV-based (Clontech, Palo Alto, CA, USA) retroviral vector,
pCMSVpuro.
The preparation of recombinant retroviruses and the infection
procedures have been previously described (Naviaux et al, 1996).
HDK1 cells were infected with the prepared retroviruses, LXSN-
16E6, LXSN-16E7, LXSN-16E6E7, or the control LXSN. The
infected cells were selected in the presence of 50mgml
 1 of
G418. SiHa, CaSki and C33A cells were infected with either the
MSCV-puro or MSCV-puroBPV1E2 viruses and selected with
1mgml
 1 of puromycin.
Immunoblot analysis
We generated a rabbit polyclonal antibody against a synthetic
peptide, amino acids 50–66 (CNFKPDIQEIPKKPKVEE) of hWAPL
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s(termed anti-hWAPL-N). Immunoblot analyses were performed as
previously described (Kiyono et al, 1997). Antibodies against
hWAPL (anti-hWAPL-N), p53 (Oncogene Science, Cambridge,
MA, USA, DO-1), and the anti-HPV16 E7 (ZYMED, South San
Francisco, CA, USA, 8C9) were used at a dilution of 1/1000.
Animals and treatments
Guidelines for the care and use of animals were approved by the
animal research centre in Tokyo Medical University. BALB/cAJc1-
nu female mice (4 weeks old) were purchased from Charles River
Japan, Inc. (Kanagawa, Japan). The individual mice were injected
with E4 10
7 SiHa cells suspended in 200ml of PBS. Upon the
development of a tumour from the injected SiHa cells 1 week after
injection, we injected either an active siRNA specific for hWAPL or
the negative control siRNA at the indicated time points (Figures 2A
and 3). The nucleotide sequences of the siRNAs were as previously
described (Oikawa et al, 2004). The active siRNA specific for
hWAPL corresponds to siRNA(I) in the previous study (Oikawa
et al, 2004). The injection materials were generated as follows: In
Figure 2, the siRNAs were synthesised by in vitro transcription
using a Silencer siRNA Construction Kit (Ambion, Austin, TX,
USA). One microlitre of 10mM siRNA and 2ml of Oligofectamine
Reagent (Invitrogen Japan, Tokyo, Japan) were diluted into 89ml
and 8ml of Opti-MEM I (Invitrogen Japan), respectively. After a 10-
min incubation, the diluted reagents were combined and incubated
for an additional 20min. The siRNA-Oligofectamine mixture was
then injected into the mouse at the tumour site. In Figure 3, 1mlo f
10mM siRNA and 74ml of 2% atelocollagen (Koken Co. Ltd, Tokyo,
Japan) (Takei et al, 2004) were mixed on ice, and then the siRNA-
atelocollagen mixture was injected into mouse at the tumour site.
Statistical analysis
The data were analysed using the Student’s t-test, and Po0.001
were considered to indicate significant differences.
RESULTS
HPV oncoproteins E6 and E7 induce hWAPL
We examined whether HPV-16 E6 and E7 oncogene products
influence hWAPL expression. We infected normal human
epidermal keratinocytes from adult skin tissue (HDK1) with
HPV-16 E6- and E7-expressing retroviruses, and observed that
both HPV-16 E6 and E7 induce hWAPL expression (Figure 1A). E6
and E7 expression levels were confirmed by monitoring p53
degradation and E7 antibody staining, respectively (Figure 1A).
To confirm that hWAPL expression is inducible by E6 and E7,
we also examined whether repression of E6 and E7 expression
causes hWAPL reduction in cervical cancer-derived cell lines.
Because the papillomavirus E2 protein represses E6/E7 transcrip-
tion by binding the HPV early promoter (Hwang et al, 1993, 1996;
Dowhanick et al, 1995; Francis et al, 2000), we analyse the effect of
E2 on hWAPL expression. We observed a significant reduction of
hWAPL protein levels after the infection of HPV-16 E6- and E7-
expressing cervical cancer cell lines, such as CaSki and SiHa, with
the retrovirus encoding E2 (Figure 1B). The HPV-negative cervical
cancer cell line C33A, however, did not exhibit significant changes
in hWAPL protein levels after E2 retrovirus infection (Figure 1B).
These results demonstrate that hWAPL can be induced by HPV E6
and E7 oncoproteins.
The mechanism of hWAPL induction by E6 and E7 has not yet
been elucidated. Although both E6 and E7 contribute transforma-
tion of human keratinocytes, functions of these proteins are
different. hWAPL induction by the combination of E6 and E7,
however, showed similar level to that by either E6 or E7 alone
(Figure 1A). Thus, hWAPL transcription may possibly respond to a
particular precancerous cell states induced by E6 and/or E7. In
fact, HPV-positive normal cervical tissue samples exhibited a low
level of hWAPL expression (Oikawa et al, 2004), and C33A, an
HPV-negative uterine cervical cancer-derived cell line, showed
high hWAPL expression (Figure 1B, and data not shown),
suggesting that hWAPL expression is more closely related with
cervical carcinogenesis than HPV infection, as previously men-
tioned (Oikawa et al, 2004). Nevertheless, although HPV infection
does not always induce hWAPL expression, E6 and E7 oncopro-
teins are still likely to be associated with hWAPL expression in
cervical cancers.
hWAPL exhibits great potential as a therapeutic target
We previously observed that repression of hWAPL expression by a
specific siRNA inhibited cell growth in various cervical cancer-
derived cell lines such as SiHa, CaSki (Oikawa et al, 2004) and
C33A (data not shown) in vitro. Thus, we next investigated the
possibility that hWAPL might be a novel cancer therapeutic target
molecule. We generated tumours in nude mice by subcutaneous
injection of SiHa cells. At 1 week after injection of the tumour cells,
we measured tumour sizes using caliper squares and then injected
siRNA into the tumours on alternate days for 3 weeks (Figure 2A).
The growth of tumours injected with the active siRNA specific for
hWAPL was repressed in comparison with untreated tumours or
tumours injected with negative control siRNA (Figure 2A,B). We
observed necrosis in the tumours injected with the active siRNA
(Figure 2C). In contrast, untreated or control tumours were viable
(Figure 2C). We also observed similar effects of the siRNA on
tumours arising from another cervical cancer-derived cell line,
CaSki (data not shown). These results demonstrate that hWAPL
may have potential as a therapeutic target, particularly in cervical
cancer.
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Figure 1 (A) HPV-16 E6 and E7 expression induces increased
expression of hWAPL. hWAPL protein was induced by HPV E6 and E7
oncoprotein expression in HDK1 cells (passage 5), as determined by
Western blotting. E6 induced p53 degradation (lanes 2, E6 and 4, E6E7). A
Western blot showing HPV-16 E7 protein levels is provided in the bottom
panel. (B) BPV1 E2 suppressed hWAPL expression. hWAPL protein levels
were reduced by exogenous BPV1 E2 expression in the HPV 16 E6- and
E7-expressing cell lines, CaSki and SiHa, as determined by Western blot
analysis.
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et al, 2004) and the durability of the effects may be insufficient for
clinical application. In fact, although we injected the hWAPL
siRNA into tumours on alternate days, the repression of the
tumour growth was not preserved in a few cases (Figure 2A and
data not shown). Recently, a new gene transfer method using
atelocollagen has been established (Ochiya et al, 1999). Atelocolla-
gen is expected to increase cellular uptake, nuclease resistance, and
prolonged release of siRNAs adiministered into tumours because
of its unique property that it is a liquid at 41C and a gel at 371C
(Ochiya et al, 1999; Takei et al, 2004). Furthermore, Takei et al
revealed that atelocollagen contributes the increased stability of
siRNAs injected in tumours. Thus, we generated tumours in nude
mice by subcutaneous injection of SiHa cells again, and then
monitored the growth of the tumours injected with active siRNA or
negative control siRNA mixed with atelocollagen (Figure 3). The
injection was performed at only 4 time points of 0, 5th, 10th and
20th day for 35 days. As shown in Figure 3, active siRNA with
atelocollagen dramatically suppressed tumour growth.
DISCUSSION
Recent findings show that the targeted inactivation of oncogenes
could be a specific and effective treatment for cancer (Felsher,
2003). For uterine cervical cancer, HPV E6 and/or E7 were shown
to be a strong candidate as a target for gene-specific therapy (Jiang
and Milner, 2002; Butz et al, 2003; Yoshinouchi et al, 2003).
However, many subtypes of high-risk HPV have been detected in
cervical cancers although HPV types 16 and 18 are great majority
of cervical carcinomas (Nakagawa et al, 2000). Thus, for clinical
application of E6 and E7 siRNAs, various nucleotide sequences
may be required for the respective types of HPV. In this study, we
have demonstrated that an siRNA of hWAPL induces tumour
regression in vivo. This anticancer effects by the hWAPL siRNA
stands comparison with the effects of the E6 siRNA (Jiang and
Milner, 2002; Butz et al, 2003; Yoshinouchi et al, 2003). Therefore,
we expect that hWAPL is one of strong candidates as a target for
uterine cervical cancer therapy.
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Figure 2 An active siRNA inhibiting hWAPL expression suppressed the
growth of subcutaneous tumours derived from SiHa cells inoculated into
nude mice. (A) Tumour growth curves. The tumour volume (mm
3) was
approximated by multiplication of the major axis, the minor axis, and the
height of each tumour. Each data point represents the mean of eight
samples. Bars, s.e. (B) Weights of the tumours in nude mice 25 days after
the first siRNA injection. Each data point represents the mean of eight
samples. Bars, s.e. *Po0.001 vs negative control. **Po0.001 vs no
treatment. (C) Representative histology of the subcutaneous tumours in
nude mice. The excised tumours were subjected to paraffin sectioning,
then stained with haematoxylin and eosin.
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Figure 3 Atelocollagen increases antitumour effects of hWAPL siRNA.
The growth curves of subcutaneous tumours injected with active or
negative control siRNA mixed with atelocollagen were shown. The tumour
volume (mm
3) was approximated by multiplication of the major axis, the
minor axis, and the height of each tumour. Each data point represents the
mean of four samples. Bars, s.e.
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